Resistance to Flu Drug Could be Greater than Previously Thought


Results of a small study from Japan in this weeks issue of The Lancet suggest that the emergence of influenza viruses which are resistant to a widely used influenza drug may be more common than previously thought.

A drug class called neuraminidase inhibitors are an effective option for treating influenza; the drugs act by blocking an enzyme which usually allows the influenza virus to escape and infect other cells. The neuraminidase inhibitor oseltamivir is widely used, although no research has established the risk of the emergence of viruses resistant to this drug during clinical use.

Yoshihiro Kawaoka (University of Tokyo) and colleagues investigated oseltamivir resistance in a group of children treated for influenza. Children, being more susceptible to influenza than adults, are thought to be a useful group to study as they could provide a model similar to that of a general population during a flu pandemic.

Influenza A viruses (H3N2) collected from 50 Japanese children before and during treatment with oseltamivir were analyzed. Neuraminidase mutations were found in viruses from nine patients (18 percent). Oseltamivir-resistant viruses were first detected four days after the start of treatment and on each successive day of the study.

Dr. Kawaoka comments: Oseltamivir-resistant mutants in children being treated for influenza with oseltamivir arise more frequently than previously reported. Furthermore, children can be a source of viral transmission, even after five days of treatment with oseltamivir.

In an accompanying commentary (p. 733), Anne Moscona (Mount Sinai School of Medicine, New York) concludes: We need more information on the emergence of resistance, especially in oseltamivir-treated patients, and we urgently need to know whether resistant variants, such as those identified in Kisos study, are transmissible. The development of the neuraminidase inhibitors has been a true success story; protein structural analysis directly applied to preventing and treating a major infectious threat. Let us take Kiso and colleagues study as an energizing mandate to learn more about the incidence and mechanisms of resistance to the neuraminidase inhibitors, so that appropriate strategies can be developed for their use during the next pandemic.

Source: The Lancet

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content